Reduced ADK expression can make liver more susceptible to carcinogenic damage

NewsGuard 100/100 Score

A new study has shown that reduced adenosine kinase expression (ADK) in the liver can make it more susceptible to carcinogenic damage and the development of liver cancer. Combined results from the study of human liver cancer samples and mice with reduced levels of ADK expression support these findings, reported in Journal of Caffeine and Adenosine Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

In the article entitled "Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen," Rkia El-Kharrag, PhD, Randy Owen, BSc, and Detlev Boison, PhD, Legacy Research Institute, Portland, OR, showed that 64% of patients with liver cancer had lower ADK expression. ADK is highly expressed in the liver, where it regulates adenosine levels and is important in controlling hepatic metabolism. The researchers used transgenic technology to generate mice with reduced ADK expression and then exposed them to a carcinogen to study the effects on the animals' body weight and survival.

"These results might represent a very significant advance in the field. Further studies should confirm if adenosine kinase represents a new biomarker or a pharmacological target in liver cancer," says Editor-in-Chief of Journal of Caffeine and Adenosine Research Sergi Ferré, MD, PhD, and his research colleagues in the Integrative Neurobiology Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD.​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quibim introduces QP-Liver for enhancing liver disease diagnosis through MRI analysis